ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  Related Studies  
Biologic Effects of Dehydroepiandrosterone (DHEA) in Humans

This study has been completed.
Information provided by National Institute on Aging (NIA)

This Tabular View shows the required WHO registration data elements as marked by

Descriptive Information Fields
Brief Title  Biologic Effects of Dehydroepiandrosterone (DHEA) in Humans
Official Title  Biologic Effects of DHEA in Humans
Brief Summary

The purpose of this study is to determine whether DHEA replacement therapy decreases abdominal fat and improves insulin sensitivity.

Detailed Description

Studies on rats and mice have shown that the adrenal hormone dehydroepiandrosterone (DHEA) reduces abdominal visceral fat and protects against insulin resistance. This study was done to learn if DHEA replacement therapy decreases abdominal obesity and improves insulin action in humans.

Participants were randomly assigned to receive 50 mg per day of DHEA or a placebo at bedtime for 6 months. Participants underwent magnetic resonance imaging (MRI) and oral glucose tolerance tests at the beginning and conclusion of the study. Other tests included measurements of hormones and lipids.

Study Phase
Study Type  Interventional
Study Design  Prevention, Randomized, Double-Blind, Placebo Control
Primary Outcome Measure  6-month change in visceral and subcutaneous abdominal fat
Secondary Outcome Measure 
Condition  Aging
Obesity
Insulin Resistance
Intervention  Drug: DHEA
MEDLINE PMIDs 15536111,   9374813,   9467418,   11106916
Links
Recruitment Information Fields
Recruitment Status  Completed
Enrollment  56
Start Date  June 2001
Completion Date February 2004
Eligibility Criteria 

Inclusion Criteria:

  • 65 to 78 years old
  • Physically healthy
  • Non-smoker
  • On stable medications for at least 6 months
  • Stable body weight for the past year

Exclusion Criteria:

  • Serious active medical problems
  • Hormone therapy
  • Abnormal PSA (prostate specific antigen) in men
Gender Both
Ages 65 Years to 78 Years
Accepts Healthy Volunteers Yes
Contacts ††
Location Countries  United States
Administrative Information Fields
NCT ID  NCT00099697
Organization ID AG0013
Secondary IDs †† 5P60AG013629, 5R01AG020076, 5K23RR016191, 3P30DK056341, 5P60DK020579, 2M01RR000036
Study Sponsor  National Institute on Aging (NIA)
Collaborators †† National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Center for Research Resources (NCRR)
Investigators 
Principal Investigator:     John O. Holloszy, MD     Washington University School of Medicine    
Principal Investigator:     Dennis T. Villareal, MD     Washington University School of Medicine    
Information Provided By National Institute on Aging (NIA)
Verification Date December 2004
First Received Date  December 17, 2004
Last Updated Date June 23, 2005

 †    Required WHO trial registration data element.
††   WHO trial registration data element that is required only if it exists.




Links to all studies - primarily for crawlers